Vertex Pharmaceuticals Incorporated (VRTX) said the European Medicines Agency's CHMP adopted a positive opinion for the label extension of KAFTRIO in a combination regimen with ivacaftor, for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Create Account

Dark

chart

exchange

Check out our Level2View

Vertex Pharmaceuticals Incorporated (VRTX) said the European Medicines Agency's CHMP adopted a positive opinion for the label extension of KAFTRIO in a combination regimen with ivacaftor, for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

RTTNews | Nov 12, 2021 07:39AM EST

07:39 Friday, November 12, 2021 (RTTNews.com) - Vertex Pharmaceuticals Incorporated (VRTX) said the European Medicines Agency's CHMP adopted a positive opinion for the label extension of KAFTRIO in a combination regimen with ivacaftor, for the treatment of cystic fibrosis in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

KAFTRIO in combination with ivacaftor is approved in the European Union for the treatment of cystic fibrosis in patients ages 12 years and older who have at least one copy of the F508del mutation in the CFTR gene.

Read the original article on RTTNews ( https://www.rttnews.com/3241970/vertex-pharma-chmp-adopts-positive-opinion-for-label-extension-of-kaftrio-to-include-6-11-age-group.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved